[go: up one dir, main page]

WO2014175676A1 - Composition topique pour la peau contenant du gincénoside rf - Google Patents

Composition topique pour la peau contenant du gincénoside rf Download PDF

Info

Publication number
WO2014175676A1
WO2014175676A1 PCT/KR2014/003593 KR2014003593W WO2014175676A1 WO 2014175676 A1 WO2014175676 A1 WO 2014175676A1 KR 2014003593 W KR2014003593 W KR 2014003593W WO 2014175676 A1 WO2014175676 A1 WO 2014175676A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
ginsenoside
external
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2014/003593
Other languages
English (en)
Korean (ko)
Inventor
김동현
류권렬
이옥찬
염명훈
조준철
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Priority to HK16101705.6A priority Critical patent/HK1213772B/zh
Priority to CN201480029495.9A priority patent/CN105246489B/zh
Publication of WO2014175676A1 publication Critical patent/WO2014175676A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/10—Preparations for permanently dyeing the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/524—Preservatives

Definitions

  • the present invention can provide acne and skin trouble improvement effect, skin convergence and pore contraction effect by containing ginsenoside Rf, and can provide skin color improvement effect, hair growth improvement, white hair improvement, anti dandruff and antiseptic effect. It relates to a composition.
  • Human skin is the body's primary protective barrier, which protects the body's organs from changes in temperature and humidity, and from external environmental stimuli such as ultraviolet rays and pollutants. Undergo a change. That is, internally, the secretion of various hormones that regulate metabolism decreases, and the function of immune cells and the activity of cells decreases, thereby reducing the biosynthesis of immune proteins and constituent proteins necessary for living organisms.
  • free radicals and free radicals increase, thereby reducing the thickness of the skin, increasing wrinkles, reducing elasticity, Skin color becomes dull, skin problems frequently occur, blemishes, freckles and blotch also increase, the color becomes worse and the skin tone becomes darker.
  • the skin condition is improved by adding bioactive substances obtained from various known animals, plants, and microorganisms to cosmetics. Efforts have been made.
  • Ginsenoside Rf is a type of saponin contained in ginseng, and its physiological activities such as lipid peroxidation inhibitory and alcohol-induced brain developmental defense, and voltage-dependent calcium channel inhibition (Nah, et al., Proc. Natl. Acad. Sci. USA, 92, 8739-8743, 1995) and anti-pain efficacy (Shin et al., Submited, 1997), but it is known to improve acne and skin troubles of a composition containing ginsenoside Rf as an active ingredient. There have been no reports on the effects, skin convergence and pore contraction effects, skin color enhancement, hair growth, white hair improvement, antidandruff and antiseptic effect.
  • ginsenoside Rf can provide acne and skin trouble improvement effect, skin convergence and pore contraction effect, and can improve skin coloration, hair growth, white hair improvement, antidandruff and antiseptic effect. Discovered and completed the present invention.
  • ginsenoside Rf can provide acne and skin trouble improvement effect, skin convergence and pore contraction effect, skin color improvement effect, hair growth improvement, white hair improvement, anti dandruff and antiseptic effect It is providing the skin external preparation composition shown.
  • the present invention provides a skin external preparation composition for improving acne containing ginsenoside Rf as an active ingredient.
  • the present invention provides a skin external preparation composition for improving color and skin tone containing ginsenoside Rf as an active ingredient.
  • the present invention also provides a topical skin composition for reducing pores containing ginsenoside Rf as an active ingredient.
  • the present invention also provides a composition for promoting hair growth containing ginsenoside Rf.
  • the present invention also provides a composition for preventing hair loss containing ginsenoside Rf.
  • the present invention also provides a composition for anti-dandruff containing ginsenoside Rf.
  • the present invention also provides a natural preservative composition containing ginsenoside Rf.
  • composition of the present invention can provide anti-inflammatory, acne and skin trouble improvement effect, skin convergence and pore contraction effect by containing ginsenoside Rf, and improves skin complexion, hair growth, white hair improvement, anti dandruff and antiseptic effect. Can provide.
  • composition according to the present invention contains ginsenoside Rf as an active ingredient.
  • Ginsenoside Rf used in the present invention has a structure represented by the following Chemical Formula 1.
  • Ginsenoside Rf of the present invention can be extracted from plants, can be used synthesized according to methods known in the art, and may be commercially available. Ginsenoside Rf can also be obtained from ginseng extract.
  • the type of ginseng used at this time is not particularly limited, and ginseng, red ginseng, white ginseng, taeguksam, misam and the like can be used.
  • the ginseng extract is contained not only in the leachate obtained by leaching and transferring from ginseng, but also in the concentrate obtained by partially or fully concentrating the leachate, or in stagnation, whole, regular, liquid extract and ginseng prepared by drying the concentrate again.
  • the chemicals that exert the main effect include all of the plant itself, and extracts from all parts of ginseng, such as stems, roots, leaves, flowers, fruits, can be used and are not limited to extracts of any particular part.
  • a method for extracting ginsenoside Rf from ginseng extract may use a known method.
  • the ginsenoside Rf may be separated from the ginseng extract after preparing ginseng extract with water or an organic solvent by a method well known in the art.
  • the organic solvent used in the present invention may be selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate, chloroform and a mixed solvent of these organic solvents and water, and preferably 80% ethanol is used.
  • the extraction temperature is preferably 10 ⁇ 80 °C, it can be extracted for 3 to 24 hours. If the extraction temperature and extraction time is out of the extraction efficiency may decrease or change of components may occur.
  • the composition of the present invention preferably contains the ginsenoside Rf in an amount of 0.001 to 50% by weight based on the total weight of the composition. This is because when the content of the active ingredient is less than 0.001% by weight, the efficacy and effect by the above ingredients are weak, and when the amount of the active ingredient exceeds 50% by weight, there is a problem of skin safety or formulation.
  • composition of the present invention can be used as an external preparation composition for improving acne, which is excellent in antibacterial effect, in particular, antibacterial effect against acne causing bacteria, and also provides an anti-inflammatory effect.
  • composition of the present invention can be used as an external skin composition for improving color and skin tone, and when applied to the skin, it smoothly supplies nutrients to the skin by promoting capillaries and promotes blood circulation and inhibits skin aging to improve color and skin tone. The effect is excellent.
  • composition of the present invention can be used as a skin external preparation composition for pore reduction, sebum control and skin trouble improvement, which suppresses excessive secretion of sebum when applied to the skin, promotes free radical removal and collagen synthesis to shrink pores.
  • the effect of suppressing skin problems is excellent by reducing the expression of inflammatory factors.
  • the composition of the present invention can be used as a composition for promoting hair growth, which promotes hair growth by promoting the transition of the resting hair cycle to the growing hair cycle, and also promotes the production of new hair, as well as promoting healthy hair. It includes growing, and provides the effect of preventing and suppressing the phenomenon of hair falling off from the scalp or the condition of hair growth or thinning.
  • the composition of the present invention can be used as a composition for preventing white hair, and increases the MITF expression of melanocytes to activate melanocytes and promote melanin synthesis, thereby preventing the induction of white hair and providing an effect of promoting hair loss.
  • composition of the present invention can be used as an anti-dandruff skin external composition, which effectively discharges toxins accumulated in the hair and scalp to cleanse the scalp, inhibit the growth and growth of dandruff bacteria, and prevent the scalp inflammatory reaction, and also active It has an excellent antioxidant effect that inhibits the production and action of oxygen, so it can provide the effect of calming and strengthening the scalp and strengthening its natural defense.
  • composition of the present invention can be used as a natural preservative composition, and because it is a natural ingredient, it provides an effect that is excellent in preservative effect and harmless to human body.
  • composition according to the invention may be formulated containing a cosmetically or dermatologically acceptable medium or base.
  • a cosmetically or dermatologically acceptable medium or base for example emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) and non-obtained by dispersing an oil phase in solution, gels, solids, pasty anhydrous products, aqueous phases.
  • It may be provided in the form of an ionic vesicle dispersant or in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. It may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
  • These compositions can be prepared according to conventional methods in the art.
  • topical skin composition of the present invention when used for the prevention of dandruff, hair growth or white hair, it may be formulated as a composition for scalp and hair, and the formulation is not particularly limited, for example, hair tonic, hair nourishing cosmetics, scalp It can be formulated as a treatment, hair treatment, hair shampoo, hair rinse, hair lotion or scalp hair combination treatment and the like.
  • the composition according to the present invention is a fatty substance, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic.
  • a fatty substance an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic.
  • adjuvants conventionally used in the
  • composition of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.
  • test examples and formulation examples are provided only for the purpose of illustration to help the understanding of the present invention is not limited to the scope and scope of the present invention by the following examples.
  • Ginsenoside Rf for testing the efficacy of the composition of the present invention was purchased from Ambo laboratory.
  • Nutritional cream was prepared in a conventional manner according to the composition of Table 1 (unit: wt%).
  • LDPI Laser Doppler Perfusion Imager; periscan PIM II, Perimed (stochholm, Sweden)
  • LDPI is a well-known and currently used device for measuring blood circulation in the skin, and is a very sensitive device that can measure not only the speed and amount of blood in capillaries of the skin but also the flow in the small arteries and the venous veins.
  • the cosmetic composition according to the present invention significantly increased the skin blood flow than Comparative Formulation Example 1 containing no ginsenoside Rf, it was confirmed that the blood color is improved through the promotion of this blood circulation. . This ultimately suggests that the cosmetic composition containing ginsenoside Rf according to the present invention can contribute effectively to the skin's nutrient delivery, inhibit skin aging and delay.
  • Comparative Formulation Example 1 containing no ginsenoside Rf according to the present invention did not show significant skin tone improvement effect, while Formulation Example 1 containing ginsenoside Rf as an active ingredient was higher than before use. It was confirmed that the skin tone after use is much improved.
  • Ginsenoside Rf according to the present invention was measured by comparing collagen biosynthesis promoting effect with TGF- ⁇ .
  • fibroblasts were seeded by 10 5 per hole in 24 wells and cultured until 90% growth. This was incubated in serum-free DMEM medium for 24 hours, and then treated with 10 g / ml of ginsenoside Rf and TGF- ⁇ of the present invention dissolved in serum-free medium, and incubated in a CO 2 incubator for 24 hours. These supernatants were removed and procollagen increased or decreased using a procollagen type (I) ELISA kit (procollagen type (I); # MK101, TAKARA (Shiga, Japan)). The results are shown in Table 4, and the synthetic ability of collagen was compared with the non-treated group as 100.
  • procollagen type (I) ELISA kit procollagen type (I); # MK101, TAKARA (Shiga, Japan
  • ginsenoside Rf according to the present invention was confirmed to exhibit a higher level of collagen synthesis than the positive control group TGF- ⁇ . Therefore, it was confirmed that ginsenoside Rf according to the present invention can reduce the enlarged pores by increasing the amount of collagen production around the pores.
  • Comparative Formulation Example 1 does not have a pore reduction effect, but in the case of Formulation Example 1 shows a pore reduction effect that can be visually confirmed, ginsenoside Rf according to the present invention reduces the size of the pores It was found that the effect was excellent.
  • HEK293 cells were transfected with p3 ⁇ FLAG-CMV-5 ⁇ R2 and cultured in a 24 well plate at 2.5 ⁇ 10 5 cells per well (Park et al., 2003, JDS. Vol. 31, pp. 191-98). The next day, a new medium with enzyme substrate and inhibitor was added. 0.05 ⁇ Ci [ 14 C] testosterone (Amersham Pharmacia biotech, UK) was used as the substrate of the medium.
  • ginsenoside Rf was added and incubated for 2 hours at 37 ° C. in a 5% CO 2 incubator. At this time, the ginsenoside Rf was not used as a negative control group, the pinasteride (finasteride) was used as a positive control group. Thereafter, the culture medium was collected, the steroid was extracted with 800 ⁇ l ethyl acetate, the organic solvent layer was separated, dried, and the remaining residue was dissolved in 50 ⁇ l ethyl acetate. The silica plastic sheet kieselgel 60 F254 ) was developed using ethyl acetate-hexane (1: 1) as a solvent.
  • 5 ⁇ -reductase which converts testosterone to dihydrotestosterone, binds to a receptor protein in the cytoplasm, enters the nucleus, activates sebaceous gland cells, promotes differentiation, and hypersecretes sebum in sebaceous glands. It was confirmed that ginsenoside Rf effectively inhibits the conversion of testosterone to dihydrotestosterone, and has a superior inhibitory effect than finasteride, which is known to inhibit the activity of 5 ⁇ -reductase. Therefore, it was confirmed that ginsenoside Rf can suppress sebum hypersecretion by effectively inhibiting the activity of 5 ⁇ -reductase.
  • Formulation Example 2 and Comparative Formulation Examples 2 to 3 were prepared according to the ingredients and the contents (% by weight) shown in Table 8 below. Specifically, Formulation Example 2 is a mixture of ginsenoside Rf, Comparative Formulation Example 2 does not contain any active ingredients for improving acne skin, Comparative Formulation Example 3 is a standard to be used as a reference for antimicrobial activity It contains erythromycin, which is widely used as an acne treatment.
  • the preparation method of Formulation Example 2 and Comparative Formulation Examples 2-3 is as follows.
  • the components of phase A in Table 8 were completely dissolved, and the components of phase B were completely dissolved in a separate dissolution tank, and then mixed and solubilized by adding phase B to phase A.
  • the ingredients of phase C were added thereto according to the blending ratios described in Table 8 to homogenize the mixing and then filtered to prepare the compositions.
  • Table 8 division Formulation Example 2 Comparative Formulation Example 2 Comparative Formulation Example 3 A Deionized Water To 100 To 100 To 100 EDTA-2Na 0.02 0.02 0.02 glycerin 5.0 5.0 5.0 B ethanol 2.0 2.0 2.0 PEG-60 hydrogenated castor oil 0.4 0.4 0.4 Perfume 0.04 0.04 0.04 C Ginsenoside Rf 5.0 - - Erythromycin - - 5.0
  • the antibacterial test method for acne bacteria was as follows.
  • Propionibacterium acnes was used as a culture broth inoculated in BHI broth and anaerobic culture.
  • test bacteria 0.15 ml of the test bacteria was added to 15 ml of BHI broth (pH 6.8) or LB broth (pH 4.5) and mixed well as a dilution solution.
  • the antibacterial activity test results for acne bacteria are shown in Table 9 below. MIC is expressed in terms of the concentration of the active ingredient contained in the formulation.
  • a mouse fibroblast cell line, 3T3-L1 cells was loaded with DMEM (Dulbeco's modified eagle's medium, GIBCO BRL, Life Technologes) medium containing 10% fetal bovine serum (FBS).
  • DMEM Dulbeco's modified eagle's medium, GIBCO BRL, Life Technologes
  • FBS fetal bovine serum
  • the well culture plates were attached at 1 ⁇ 10 5 cells / well. After 2 days, it was again exchanged with fresh DMEM (containing 10% FBS) medium and incubated for 2 days.
  • the cultured cells were then induced to differentiate into DMEM (containing 10% FBS) containing 1 ⁇ g / ml insulin, 0.5 mM IBMX and 0.25 ⁇ M dexamethasone, and ginsenoside Rf and caffeine. After 2 days of treatment 50 ⁇ M was exchanged for DMEM containing insulin and incubated for 5 days. After 5 days, the cells were exchange
  • ginsenoside Rf used in the present invention can be seen that not only the amount of fat accumulated in adipocytes, but also has a superior lipid synthesis inhibitory effect than caffeine, a known lipid synthesis inhibitor. . Therefore, sebum is reduced by inhibiting lipid synthesis, thereby suppressing the occurrence of acne.
  • Formulation Example 2 did not recur acne compared to Comparative Formulation Example 2, it can be seen that there is an excellent effect on the overall acne improvement.
  • Comparative Formulation Example 3 containing an antimicrobial activity standard shows an acne-improving effect, but due to its strong skin irritation in use, it may not be suitable for long-term use, but the composition according to the present invention has no irritation for long-term use. Even appeared to be appropriate.
  • a shampoo in the composition of Table 12 To prepare a shampoo in the composition of Table 12. Specifically, the surfactant and ethylene glycol distearate are added to purified water, heated to 80 ° C., uniformly dissolved, and then slowly cooled to 40 ° C. under stirring, and the active ingredient and preservative according to the present invention are added to the mixture. A viscosity modifier, a perfume, and a hair conditioner were added and mixed, followed by cooling to room temperature under stirring.
  • Hair loss treatment of minoxidil is known as mitochondrial potential potassium ion channel openers (K ATP channel opener), a representative drug used in the treatment of androgenetic alopecia.
  • K ATP channel opener mitochondrial potential potassium ion channel openers
  • To evaluate the mechanism of minoxidil the treatment of toltamide (SIGMA AlDRICH, T0891), which blocks the K ATP channel in fibroblasts constituting the dermis of the scalp, inhibits cell proliferation, and then opens potassium ion channels to allow cell proliferation. A recovering test method was used.
  • a mouse embryonic fibroblast cell line (NIH3T3) cell line was used.
  • the cell line is a cell line in which the fibroblast cell line isolated from NIH Swiss mouse embryo was naturally immortalized by 3T3 protocol.
  • the cell line was incubated in DMEM (Gibco BRL, Gaithersburg, MD, USA) containing 10% FBS for 24 hours in an incubator maintained at 5% CO 2 , 37 °C.
  • NIH3T3 was placed in a 96-well plate and incubated in a 37 ° C.
  • the absorbance of the dissolved melanin was measured at 405 nm using a microplate reader (Synergy2, BioTek (VT, USA)). The result of comparing the melanin production promoting effect of ginsenoside Rf with the control is shown in Table 16 below.
  • Table 16 sample Melanin Synthesis (%) DMSO (0.1%) 100 IBMX (100 ⁇ M) 120 Ginsenoside Rf (10 ppm) 112 Ginsenoside Rf (50 ppm) 123
  • Rf was treated with 10 ppm, and the protein was obtained after incubation at 37 ° C. for 24 hours, 48 hours, and 72 hours.
  • the protein thus obtained was subjected to western blot using MITF and tyrosinase antibody. Protein extraction and Western blot were usually performed by standard methods used by those skilled in the art. After western blot the results are shown in Table 17 below by comparing the negative control to 100.
  • Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa strains used in the experiment were tested on Tryptic Soy Broth.
  • Candida albicans and Aspergillus niger strains were cultured in Sabouraud Dextrose Broth. Incubate 1/100 (Candida albicans) in each medium The strain was diluted 1/10) was used as the test bacteria.
  • Aspergillus niger used a spore suspension prepared to be 2 ⁇ 10 8 cfu / ml as the test cell solution.
  • test bacteria 0.15 ml of the test bacteria was added to 15 ml of each medium, and a well mixed solution was used as a diluting solution.
  • 16 ⁇ l of 10 ppm of ginsenoside Rf was added to a 96-well plate, and 184 ⁇ l of the diluted solution was added thereto. The remaining wells were added with 100 ⁇ l of dilution solution. After mixing well the mixture of the first row, 100 ⁇ l was taken in the second row, mixed well, and then diluted 100 times by taking 100 ⁇ l again in the third row.
  • Staphylococcus aureus Escherichia coli, Pseudomonas aeruginosa, Candida albicans, Aspergillus niger, in a 32 ° C. thermostat. niger was incubated in a 25 °C thermostat.
  • ginsenoside Rf exhibits antimicrobial activity against various strains, through which it can be predicted that ginsenoside Rf can act as a natural preservative or antimicrobial agent in the composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition contenant, comme principe actif, du gincénoside Rf, pour exercer des effets comme l'amélioration de l'acné et des troubles cutanés, l'assainissement de la peau, le resserrement des pores, et pour exercer en outre des effets comme l'amélioration du teint de la peau, l'activation de la croissance capillaire, l'amélioration des cheveux grisonnants, un effet anti-pelliculaire et un effet antiseptique.
PCT/KR2014/003593 2013-04-24 2014-04-24 Composition topique pour la peau contenant du gincénoside rf Ceased WO2014175676A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HK16101705.6A HK1213772B (zh) 2013-04-24 2014-04-24 含有人参皂苷rf的皮肤外用剂组合物
CN201480029495.9A CN105246489B (zh) 2013-04-24 2014-04-24 含有人参皂苷rf的皮肤外用剂组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2013-0045118 2013-04-24
KR1020130045118A KR102024572B1 (ko) 2013-04-24 2013-04-24 진세노사이드 Rf를 함유하는 피부 외용제 조성물

Publications (1)

Publication Number Publication Date
WO2014175676A1 true WO2014175676A1 (fr) 2014-10-30

Family

ID=51792147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/003593 Ceased WO2014175676A1 (fr) 2013-04-24 2014-04-24 Composition topique pour la peau contenant du gincénoside rf

Country Status (4)

Country Link
KR (1) KR102024572B1 (fr)
CN (4) CN105246489B (fr)
TW (1) TWI620567B (fr)
WO (1) WO2014175676A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104382920A (zh) * 2014-11-27 2015-03-04 北京师范大学 人参皂苷Rf的新应用
WO2023275204A1 (fr) * 2021-06-30 2023-01-05 L'oreal Composition comprenant au moins un (poly)glycoside d'alkyle, au moins un alcool gras, au moins un acide gras et au moins un agent alcalin

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102241974B1 (ko) 2014-09-23 2021-04-19 삼성전자주식회사 반도체 장치 및 그 제조 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100296430B1 (ko) * 1992-09-17 2001-11-05 엘뵈엠아시 러쉐르쉬 1종이상의진세노사이드계사포닌을함유하는화장료또는피부용조성물
KR20050088741A (ko) * 2004-03-03 2005-09-07 소망화장품주식회사 진세노사이드 알지2를 함유하는 사포닌 혼합물로 이루어진피부보호용 화장료 조성물
WO2008125231A1 (fr) * 2007-04-17 2008-10-23 Bayer Consumer Care Ag Ginsénosides et extraits les contenants combinés à du dexpanthénol
KR20090015127A (ko) * 2006-05-17 2009-02-11 바이엘 컨수머 케어 악티엔게젤샤프트 진세노사이드 및 이들을 함유하는 추출물의 용도
KR20090087709A (ko) * 2008-02-13 2009-08-18 주식회사 한국인삼공사 사포닌을 유효성분으로 포함하는 치주질환의 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079143A (zh) * 1992-05-26 1993-12-08 邓忠元 五合一人参油系列化妆品及其制备方法
JP2001521876A (ja) * 1997-10-23 2001-11-13 ファーマプリント・インコーポレイテッド 医薬グレードの薬用ニンジン
WO2001001816A1 (fr) * 1999-07-06 2001-01-11 Procter & Gamble Company Timbre cosmetique ou dermapharmaceutique
CN1382434A (zh) * 2001-04-20 2002-12-04 姜淑凤 润生护肤品
CN1177602C (zh) * 2002-03-20 2004-12-01 张立娟 一种治疗痤疮的中药组合物
CN100594910C (zh) * 2004-06-03 2010-03-24 昆明香格喜玛生物技术有限责任公司 具有生理活性的复方人参三醇皂苷及其制剂及用途
CN101224184B (zh) * 2006-12-13 2011-11-02 天津尖峰弗兰德医药科技发展有限公司 一种营养美白的美容产品及其制备方法
KR20080105470A (ko) * 2007-05-31 2008-12-04 (주)아모레퍼시픽 인삼 열매 추출물을 함유하는 비만 예방 및 개선용 식품조성물
CN103479694B (zh) * 2008-06-13 2016-06-29 株式会社爱茉莉太平洋 含有人参的花或人参的种子提取物的皮肤外用剂组合物
CN101732227B (zh) * 2010-01-12 2011-09-28 北京章光101科技股份有限公司 一种滋养毛囊、防脱发、固发组合物及其制造方法
CN102805719A (zh) * 2011-12-22 2012-12-05 刘卫兵 一种可食用的纯植物抗衰护肤品
CN102988229B (zh) * 2012-11-26 2015-01-14 薛美琪 一种黑参的处理工艺及黑参化妆品的制备工艺

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100296430B1 (ko) * 1992-09-17 2001-11-05 엘뵈엠아시 러쉐르쉬 1종이상의진세노사이드계사포닌을함유하는화장료또는피부용조성물
KR20050088741A (ko) * 2004-03-03 2005-09-07 소망화장품주식회사 진세노사이드 알지2를 함유하는 사포닌 혼합물로 이루어진피부보호용 화장료 조성물
KR20090015127A (ko) * 2006-05-17 2009-02-11 바이엘 컨수머 케어 악티엔게젤샤프트 진세노사이드 및 이들을 함유하는 추출물의 용도
WO2008125231A1 (fr) * 2007-04-17 2008-10-23 Bayer Consumer Care Ag Ginsénosides et extraits les contenants combinés à du dexpanthénol
KR20090087709A (ko) * 2008-02-13 2009-08-18 주식회사 한국인삼공사 사포닌을 유효성분으로 포함하는 치주질환의 치료용 조성물

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104382920A (zh) * 2014-11-27 2015-03-04 北京师范大学 人参皂苷Rf的新应用
WO2023275204A1 (fr) * 2021-06-30 2023-01-05 L'oreal Composition comprenant au moins un (poly)glycoside d'alkyle, au moins un alcool gras, au moins un acide gras et au moins un agent alcalin
FR3124724A1 (fr) * 2021-06-30 2023-01-06 L'oreal Composition comprenant au moins un alkyl(poly)glycoside, au moins un alcool gras, au moins un acide gras, et au moins un agent alcalin
US12472136B2 (en) 2021-06-30 2025-11-18 L'oreal Composition comprising at least one alkyl (poly)glycoside, at least one fatty alcohol, at least one fatty acid, and at least one alkaline agent

Also Published As

Publication number Publication date
CN107898656B (zh) 2020-12-18
TWI620567B (zh) 2018-04-11
TW201521735A (zh) 2015-06-16
KR102024572B1 (ko) 2019-09-24
CN105246489B (zh) 2019-11-12
CN108498365B (zh) 2021-06-01
HK1213772A1 (zh) 2016-07-15
CN107898656A (zh) 2018-04-13
CN108042386A (zh) 2018-05-18
CN105246489A (zh) 2016-01-13
KR20140126891A (ko) 2014-11-03
CN108498365A (zh) 2018-09-07

Similar Documents

Publication Publication Date Title
WO2014175678A1 (fr) Composition topique pour la peau contenant du gincénoside rg3
KR101928797B1 (ko) 컴파운드 ｋ를 함유하는 피부 외용제 조성물
WO2011122869A2 (fr) Composition cosmétique comprenant du coumestrol ou un extrait de fèves contenant du coumestrol, pour les soins de la peau
WO2014077568A1 (fr) Composition pour préparation de peau à usage externe, contenant une thiorédoxine
KR102021764B1 (ko) 진세노사이드 Rh4를 함유하는 피부 외용제 조성물
KR101939112B1 (ko) 진세노사이드 ｆ１을 함유하는 피부 외용제 조성물
WO2014175676A1 (fr) Composition topique pour la peau contenant du gincénoside rf
KR101909533B1 (ko) 진세노사이드 ｆ１을 함유하는 피부 외용제 조성물
KR101939111B1 (ko) 진세노사이드 ｆ２를 함유하는 피부 외용제 조성물
KR101939113B1 (ko) 진세노사이드 ｆ２를 함유하는 피부 외용제 조성물
WO2014178681A1 (fr) Composition topique pour la peau contenant du ginsenoside y
KR102048709B1 (ko) 진세노사이드 Mc를 함유하는 피부 외용제 조성물
WO2026014948A1 (fr) Composition cosmétique comprenant de l'acide chlorogénique et de la taurine
HK1213772B (zh) 含有人参皂苷rf的皮肤外用剂组合物
WO2017074022A1 (fr) Composition cosmétique contenant un ginsénoside en tant qu'ingrédient actif
HK1218077B (en) Topical composition for skin containing gincenoside mc
HK1212918B (zh) 含有人参皂苷rh4的皮肤外用剂组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14788877

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 15.02.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14788877

Country of ref document: EP

Kind code of ref document: A1